Welcome to our dedicated page for Moleculin Biotec news (Ticker: MBRX), a resource for investors and traders seeking the latest updates and insights on Moleculin Biotec stock.
Moleculin Biotech, Inc. (NASDAQ: MBRX) is a clinical-stage pharmaceutical company advancing novel therapies for resistant cancers and viral diseases. This news hub provides investors and researchers with essential updates on clinical developments, regulatory milestones, and scientific breakthroughs.
Access timely announcements about Annamycin's progress through late-stage trials for acute myeloid leukemia (AML), WP1066's immune-modulating potential, and strategic partnerships advancing oncology research. Our curated collection includes press releases on FDA designations, trial protocol updates, and peer-reviewed study publications.
Key coverage areas include non-cardiotoxic anthracycline developments, orphan drug status achievements, and preclinical data on metabolic pathway inhibitors. Bookmark this page for verified updates on Moleculin's innovative approaches to overcoming multidrug resistance in cancer treatment.
Moleculin Biotech, Inc. (Nasdaq: MBRX) presented positive preclinical data for Annamycin, a next-generation anthracycline, at the American Association for Cancer Research (AACR) Annual Meeting 2023. The research showcased Annamycin's enhanced liver accumulation, significantly exceeding doxorubicin's uptake, and demonstrated high antitumor efficacy in liver cancer models. Key findings included a six-fold increase in liver accumulation compared to doxorubicin, substantial inhibition of tumor growth, and improved survival rates in various models. Annamycin is currently under evaluation in clinical trials targeting soft tissue sarcoma lung metastases and acute myeloid leukemia. These promising results bolster future studies and potential for Annamycin as a viable treatment option for hard-to-treat tumors.
Moleculin Biotech (NASDAQ: MBRX) reported its financial results for 2022, showing a net loss of $29.0 million, up from $6.7 million in 2021. R&D expenses increased to $19.0 million, driven by heightened clinical trial activities. The company has sufficient cash, totaling $43.1 million, to fund operations into the third quarter of 2024. Recent highlights include positive data from Annamycin's trials, an 80% overall response rate for refractory AML, and Fast Track Designation from the FDA for WP1122. A conference call to discuss results will be held on March 23, 2023, at 8:30 AM ET.
Moleculin Biotech, Inc. (MBRX) announced significant updates regarding its clinical trials on March 22, 2023. The company is actively recruiting for three Phase 1b/2 trials, with one trial having recently transitioned to Phase 2. Notably, Moleculin has achieved 50% recruitment in its Phase 2 trial targeting soft tissue sarcoma (STS) lung metastases. Preliminary results from the trials indicate a 67% response rate and no cardiotoxicity associated with its lead drug, Annamycin. The company anticipates multiple data readouts and milestones throughout 2023 as it advances its pipeline for hard-to-treat cancers.
Moleculin Biotech, Inc. (Nasdaq: MBRX) announced that its abstract for the next-generation anthracycline, Annamycin, has been accepted for presentation at the AACR Annual Meeting 2023 from April 14-19, 2023 in Orlando, FL. The presentation, titled Exploration of Annamycin Organotropism, focuses on targeting liver cancers. Annamycin has shown potential in animal models for significantly improved localization over doxorubicin and reduced cardiotoxicity, enhancing its therapeutic prospects for treating acute myeloid leukemia and soft tissue sarcoma lung metastases.
FAQ
What is the current stock price of Moleculin Biotec (MBRX)?
What is the market cap of Moleculin Biotec (MBRX)?
